AlphaMadera
Medtronic Plc (MDT)
$96.54
-0.57 (-0.59%)Delayed quote.
Price history
Daily close- Start
- $90.20
- Latest close
- $96.54
- Period change
- +7.03%
- Period low
- $73.75
- Period high
- $105.35
Key metrics
- Market cap
- $123.49B
- Volume
- 8.67M
- Average volume
- 14.01M
- 52-week range
- $73.31 – $106.33
- Beta
- 0.57
- Last dividend
- $2.86
- EPS (TTM)
- $4.09
- P/E ratio
- 23.60
- Revenue (TTM)
- $37.54B
- Net income (TTM)
- $5.23B
- Total assets
- $93.31B
- Total debt
- $28.15B
- Cash and equivalents
- $1.69B
Key financials (trailing twelve months).
Company profile
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
- Sector
- Healthcare
- Industry
- Medical - Devices
- Exchange
- NYSE
- CEO
- Geoffrey Straub Martha
- Employees
- 95,000
- Headquarters
- Galway, GA, IE
- IPO date
- 1973-05-02
- Website
- https://www.medtronic.com
Financial statements
Annual, last 3 fiscal years. Most recent period first. Reported in USD.
| Metric | FY2026Apr 24, 2026 | FY2025Apr 25, 2025 | FY2024Apr 26, 2024 |
|---|---|---|---|
| Revenue | $36.36B | $33.54B | $32.36B |
| Gross profit | $23.64B | $21.91B | $21.15B |
| Operating income | $6.47B | $5.96B | $5.14B |
| EBITDA | $9.81B | $9.22B | $8.20B |
| Net income | $4.80B | $4.66B | $3.68B |
| Diluted EPS | $3.73 | $3.61 | $2.76 |
| Metric | FY2026Apr 24, 2026 | FY2025Apr 25, 2025 | FY2024Apr 26, 2024 |
|---|---|---|---|
| Cash and equivalents | $1.95B | $2.22B | $1.28B |
| Total assets | $93.03B | $91.68B | $89.98B |
| Total liabilities | $42.96B | $43.42B | $39.56B |
| Total debt | $27.96B | $28.52B | $25.02B |
| Shareholders’ equity | $49.46B | $48.02B | $50.21B |
| Metric | FY2026Apr 24, 2026 | FY2025Apr 25, 2025 | FY2024Apr 26, 2024 |
|---|---|---|---|
| Operating cash flow | $7.33B | $7.04B | $6.79B |
| Capital expenditure | -$1.90B | -$1.86B | -$1.59B |
| Free cash flow | $5.43B | $5.18B | $5.20B |
Quarterly, last 6 quarters. Most recent period first. Reported in USD.
| Metric | Q1 2027Jul 31, 2026 | Q4 2026Apr 30, 2026 | Q3 2026Jan 31, 2026 | Q2 2026Oct 31, 2025 | Q1 2026Jul 31, 2025 | Q4 2025Apr 25, 2025 |
|---|---|---|---|---|---|---|
| Revenue | $9.76B | $9.81B | $9.02B | $8.96B | $8.58B | $8.93B |
| Gross profit | $6.34B | $7.44B | $5.85B | $5.41B | $4.95B | $5.78B |
| Operating income | $1.76B | $1.56B | $1.77B | $1.69B | $1.45B | $1.44B |
| EBITDA | $2.68B | $2.64B | $2.33B | $2.52B | $2.23B | $2.27B |
| Net income | $1.47B | $1.24B | $1.14B | $1.37B | $1.04B | $1.06B |
| Diluted EPS | $1.14 | $0.96 | $0.89 | $1.07 | $0.81 | $0.82 |
| Metric | Q1 2027Jul 31, 2026 | Q4 2026Apr 30, 2026 | Q3 2026Jan 31, 2026 | Q2 2026Oct 31, 2025 | Q1 2026Jul 31, 2025 | Q4 2025Apr 25, 2025 |
|---|---|---|---|---|---|---|
| Cash and equivalents | $1.69B | $1.95B | $1.15B | $1.28B | $1.27B | $2.22B |
| Total assets | $93.31B | $93.03B | $91.48B | $91.35B | $90.97B | $91.68B |
| Total liabilities | $42.46B | $42.96B | $42.29B | $42.49B | $42.84B | $43.42B |
| Total debt | $28.15B | $27.96B | $28.07B | $29.10B | $28.61B | $28.52B |
| Shareholders’ equity | $50.23B | $49.46B | $48.98B | $48.65B | $47.89B | $48.02B |
| Metric | Q1 2027Jul 31, 2026 | Q4 2026Apr 30, 2026 | Q3 2026Jan 31, 2026 | Q2 2026Oct 31, 2025 | Q1 2026Jul 31, 2025 | Q4 2025Apr 25, 2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | $1.79B | $2.57B | $2.74B | $925.00M | $1.09B | $2.53B |
| Capital expenditure | -$503.00M | -$488.00M | -$444.00M | -$468.00M | -$504.00M | -$459.00M |
| Free cash flow | $1.29B | $2.08B | $2.30B | $457.00M | $584.00M | $2.07B |